Compound ID | 2227
Rifaphenzine
Class: Rifampicin
| Agent Type: | Semisynthetic; Direct acting; |
| Spectrum of activity: | Antimycobacterial |
| Mechanism of action: | RNA synthesis inhibitor. Binds to Mtb RNA polymerase |
| Target Pathogen: | Active against Mycobacterium tuberculosis |
| Description: | Synthetic compound; combining 2,3 diamino phenazine (clofazimine precursor) and rifampicin core; non cytotoxic to human monocytic cell line THP-1 |
| Institute where first reported: | ICMR-National Institute for Research in Tuberculosis, Chennai, India |
| Year first mentioned: | 2021 |
| Development status: | Experimental |
| External links: | |
| Citation: | https://www.nature.com/articles/s41598-020-80439-2#further-reading |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.